The Management of Hypogonadism in Aging Male Patients

References

• . Araujo AB, Esche GR, Kupelian V, . Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11): 4241–4247
   PubMed Web of Science ®Google Scholar
• . Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–731
   PubMed Web of Science ®Google Scholar
• . Vermeulen A. Androgen replacement therapy in the aging male—a critical evaluation. J Clin Endocrinol Metab. 2001;86(6):2380–2390
   PubMedGoogle Scholar
• . Tenover JS. Prevalence and management of mild hypogonadism: introduction. Int J Impot Res. 2003;15( suppl 4):S1–S2
   Google Scholar
• . Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male. 2002;5(3):170–176
   PubMedGoogle Scholar
• . Moffat SD. Effects of testosterone on cognitive and brain aging in elderly men. Ann N Y Acad Sci. 2005;1055:80–92
   PubMed Web of Science ®Google Scholar
• . Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138(3):1015–1020
   PubMed Web of Science ®Google Scholar
• . Turner HE, Wass JAH. Oxford Handbook of Endocrinology and Diabetes. Oxford, England: Oxford University Press; 2002:421–424
   Google Scholar
• . Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672
   PubMed Web of Science ®Google Scholar
• . Carnegie C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev Urol. 2004;6( suppl 6):S3–S8
   PubMedGoogle Scholar
• . Manni A, Partridge WM, Cefalu W, . Bioavailability of albumin bound testosterone. J Clin Endocrinol Metab. 1985;61(4):705–710
   PubMedGoogle Scholar
• . Chubb SA, Hyde Z, Almeida OP, . Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol. 2008;158(6):785–792
   PubMedGoogle Scholar
• . Klee GG, Heser DW. Techniques to measure testosterone in the elderly. Mayo Clin Proc. 2000;75( suppl):S19–S25
   Google Scholar
• . Wikström AM, Dunkel L. Testicular function in Klinefelter syndrome. Horm Res. 2008;69(6):317–326
   PubMedGoogle Scholar
• . Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84(3 pt 2):611–616
   PubMedGoogle Scholar
• . Keenan DM, Takahashi PY, Liu PY, . An ensemble model of the male gonadal axis: illustrative application in aging men. Endocrinology. 2006;147(6):2817–2828
   PubMedGoogle Scholar
• . Wu FC, Tajar A, Pye SR, ; European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737–2745
   PubMed Web of Science ®Google Scholar
• . Warren MP, Vu C. Central causes of hypogonadism—functional and organic. Endocrinol Metab Clin North Am. 2003;32(3):593–612
   PubMedGoogle Scholar
• . McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab. 2005;90(4):2451–2455
   PubMedGoogle Scholar
• . Smyth CM, Bremner WJ. Klinefelter Syndrome. Arch Intern Med. 1998;158(12):1309–1314
   PubMedGoogle Scholar
• . Ottesen AM, Garn ID, Aksglaede L, Juul A, Rajpert-De Meyts E. A simple screening method for detection of Klinefelter syndrome and other X-chromosome aneuploidies based on copy number of the androgen receptor gene. Mol Hum Reprod. 2007;13(10):745–750
   PubMed Web of Science ®Google Scholar
• . Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, . Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52
   PubMed Web of Science ®Google Scholar
• . Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75
   PubMed Web of Science ®Google Scholar
• . Meier C, Nguyen TV, Handelsman DJ, . Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168(1):47–54
   PubMedGoogle Scholar
• . Urban RJ, Bodenburg YH, Gilkison C, . Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269(5 pt 1):E820–E826
   Web of Science ®Google Scholar
• . Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93(1):139–146
   PubMed Web of Science ®Google Scholar
• . Rudman D, Drinka PJ, Wilson CR, . Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin Endocrinol (Oxf). 1994;40(5):653–661
   PubMedGoogle Scholar
• . Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81(12):4358–4365
   PubMed Web of Science ®Google Scholar
• . Pike CJ, Rosario ER, Nguyen TV. Androgens, aging, and Alzheimer's disease. Endocrine. 2006;29(2):233–241
   PubMedGoogle Scholar
• . Rosario ER, Pike CJ. Androgen regulation of beta-amyloid protein and the risk of Alzheimer's disease. Brain Res Rev. 2008;57(2):444–453
   PubMedGoogle Scholar
• . Pike CJ, Nguyen TV, Ramsden M, Yao M, Murphy MP, Rosario ER. Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav. 2008;53(5):693–705
   PubMedGoogle Scholar
• . Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, . Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52
   PubMed Web of Science ®Google Scholar
• . Maki PM, Ernst M, London ED, . Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab. 2007;92(11):4107–4114
   PubMed Web of Science ®Google Scholar
• . Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75(4):1092–1098
   PubMed Web of Science ®Google Scholar
• . Calof OM, Singh AB, Lee ML, . Adverse events associated with testosterone replacement in middle aged and older men: a meta-analysis of randomized, placebo controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–1457
   PubMed Web of Science ®Google Scholar
• . Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462–5468
   PubMed Web of Science ®Google Scholar
• . Corona G, Mannucci E, Petrone L, . Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18(2):190–197
   PubMed Web of Science ®Google Scholar
• . Pitteloud N, Hardin M, Dwyer AA, . Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005:90(5):2636–2641
   PubMed Web of Science ®Google Scholar
• . Laaksonen DE, Niskanen L, Punnonen K, . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–1041
   PubMed Web of Science ®Google Scholar
• . Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91(3):843–850
   PubMed Web of Science ®Google Scholar
• . You T, Nicklas BJ, Ding J, . The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci. 2008;63(4):414–419
   PubMed Web of Science ®Google Scholar
• . Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007;156(5):595–602
   PubMed Web of Science ®Google Scholar
• . Bhasin S, Parker RA, Sattler F, ; AIDS Clinical Trials Group Protocol A5079 Study Team. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92(3):1049–1057
   PubMed Web of Science ®Google Scholar
• . English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911
   PubMed Web of Science ®Google Scholar
• . Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab. 2002;87(8):3632–3639
   PubMed Web of Science ®Google Scholar
• . English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–894
   PubMed Web of Science ®Google Scholar
• . Isidori AM, Greco EA, Aversa A. Androgen deficiency and hormone-replacement therapy. BJU Int. 2005;96(2):212–216
   PubMedGoogle Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010
   PubMed Web of Science ®Google Scholar
• . Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf). 2006;65(3):275–281
   PubMed Web of Science ®Google Scholar
• . Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv. 2008;5(4):471–481
   PubMed Web of Science ®Google Scholar
• . Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71(1):216–222
   PubMed Web of Science ®Google Scholar
• . Ross RJ, Jabbar A, Jones TH, . Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur J Endocrinol. 2004;150(1):57–63
   PubMedGoogle Scholar
• . Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 1989;261(17):2525–2530
   PubMedGoogle Scholar
• . Meikle AW, Mazer NA, Moellmer JF, . Enhanced transdermal delivery of testosterone across the nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 1992;74(3):623–628
   PubMed Web of Science ®Google Scholar
• . Wang C, Swerdloff RS, Iranmanesh A, ; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–2853
   PubMed Web of Science ®Google Scholar
• . McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69–74
   PubMedGoogle Scholar
• . Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51(6):1335–1339
   PubMed Web of Science ®Google Scholar
• . Schubert M, Minnemann T, Hübler D, . Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 2004;89(11):5429–5434
   PubMedGoogle Scholar
• . Chen J, Kim J, Dalton JT. Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv. 2005;5(3):173–188
   PubMedGoogle Scholar
• . Morgentaler A. Guideline for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab. 2007;92(2):416–417
   PubMed Web of Science ®Google Scholar
• . Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156–165
   PubMedGoogle Scholar
• . Bagatell CJ, Bremner WJ. Androgens in men—uses and abuses. N Engl J Med. 1996;334(11):707–714
   PubMed Web of Science ®Google Scholar
• . American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8(6):440–456
   PubMedGoogle Scholar
• . Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213–217
   PubMedGoogle Scholar
• . Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482–492
   PubMed Web of Science ®Google Scholar
• . Viallard JF, Marit G, Mercié P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol. 2000;110(1):237–238
   PubMedGoogle Scholar
• . Tenover JL. The androgen-deficient aging male: current treatment options. Rev Urol. 2003;(5 suppl 1):S22–S28
   Google Scholar